Psychedelics: Science & Therapy

TAIP Foundation is organising an international scientific conference on October 8–9, 2026, at the National Library of Estonia, focusing on psychedelic-assisted therapy and its role in modern mental healthcare.

This two-day conference brings together scientists, physicians, psychologists, and policymakers from Estonia and abroad to explore the scientific foundations, clinical practice, and future directions of psychedelic-assisted therapy in Europe and Estonia.

The aim of the conference is to build a shared understanding of this rapidly evolving field by bringing together research, clinical experience, and international best practices.

What to expect?

Over two days, participants will gain a comprehensive overview of the development of psychedelic-assisted therapy — from research to clinical practice and regulatory approaches.

Topics include:

• the use of psilocybin, MDMA, and ketamine in mental health treatment

• clinical trials and their outcomes

• the therapeutic process and the role of psychotherapy

• international practices and regulatory models

• future developments in Europe.

October 8: Science and clinical practice
The first day focuses on the scientific foundations and clinical impact of psychedelic-assisted therapy. Topics include the use of different psychedelic substances, the development of the therapeutic process, and the integration of research and clinical experience.

October 9: Practice and the future in Europe
The second day focuses on how science is translated into practice. It highlights international experience, regulatory frameworks, and discussions on the next steps for Estonia.

International speakers

The conference will feature leading experts in the field, including:

• David Nutt – one of the world’s foremost researchers in psychedelics; professor of neuropsychopharmacology (Imperial College London).

• Lowan Stewart – developer of ketamine-assisted therapy in Norway; medical director (Axonklinikken).

• Helena Aicher – clinical practitioner in psychedelic-assisted therapy in Switzerland; researcher (University of Zurich).

• Tadeusz Hawrot – founder and CEO of PAREA
  and others.

Estonian experts and field specialists will also participate in discussions. The speaker lineup and programme are continuously updated.
Follow updates at: sataip.ee/conference.

Who is this conference for?

Mental health professionals (psychiatrists, psychologists, psychotherapists), healthcare professionals and decision-makers, researchers and students, public sector representatives, and anyone interested in understanding developments in this field from a scientific perspective.

Why does this matter?

Europe is facing a mental health crisis that requires additional treatment approaches. Mental health challenges have a significant impact on both individuals and society. According to the OECD, this impact amounts to approximately 4% of GDP — in Estonia, this equals over €1.6 billion annually.

At the same time, new approaches are being explored internationally to complement existing treatments. Psychedelic-assisted therapy is a rapidly developing field that deserves attention.

We create a space for science-based discussion, bringing together international experience and the Estonian context. Our goal is to support informed and responsible decision-making in the development of this field, expand evidence-based treatment options, and improve access to care for those who need it.

Tickets

Early bird tickets: €149 (available until May 31, limited quantity)
From June 1: €190
From September 1: €220
The conference ticket includes catering and coffee breaks. We offer participants delicious and balanced vegetarian meals. Please indicate any dietary requirements in the registration form.

Follow updates at: sataip.ee/conference

See you at the conference!